CESX yields 666666.67% · JNJ yields 2.14%● Live data
📍 CESX pulled ahead of the other in Year 1
Combined, CESX + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CESX + JNJ for your $10,000?
CES Synergies, Inc., an asbestos and lead abatement contracting firm, engages in the removal of asbestos and lead from buildings and other structures, and demolition of structures in the United States. It operates through three segments: Remediation, Demolition, and Insulation. The Remediation segment engages in the asbestos abatement, lead removal, mold remediation, and indoor air quality/duct cleaning activities; and removal of contaminated soil, animal waste removal, manual selective and complete interior demolition comprising removal of floor covering, and adhesive removal services for commercial, retail, governmental, industrial, military, and public and private schools. The Demolition segment is involved in the building separations, concrete breaking, and saw-cutting using its own man-lifts, bobcats, roll-off containers, and roll-off trucks for the hauling and disposal of construction debris. This segment also offers full-scale commercial demolition and wrecking, as well as underground and above ground storage tank removal, and full-scale site clearing, including underground pipe removal and installation. The Insulation segment engages in the re-insulation and insulation of new and remodeling projects. CES Synergies, Inc. is also involved in the construction, installation, and repair of ceilings. The company serves city, state, and federal agencies, as well as general contractors, developers, project owners, and industrial and commercial clients. CES Synergies, Inc. was founded in 1988 and is headquartered in Crystal Springs, Florida.
Full CESX Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.